ðŠ HIVæ£è ã«ãããTORCHææã®é ããè² æ
è¿å¹ŽãHIVïŒããå ç«äžå šãŠã€ã«ã¹ïŒææè ã®å¥åº·ç®¡çããŸããŸãéèŠèŠãããŠããŸããç¹ã«ãTORCHææãšåŒã°ããäžé£ã®ææçãHIVæ£è ã«äžãã圱é¿ã«ã€ããŠã®ç ç©¶ãé²ããããŠããŸããæ¬èšäºã§ã¯ãéåœã®éœåžéšã«ãããHIVæ£è ã®TORCHææã®å®æ ãæããã«ããç ç©¶ã«ã€ããŠç޹ä»ããŸãããã®ç ç©¶ã¯ãå°åç¹æã®ç«åŠããŒã¿ãå ¬è¡è¡çã®å¯Ÿå¿ã«ã©ã®ããã«å¯äžãããã瀺ããŠããŸãã
𧪠ç ç©¶æŠèŠ
æ¬ç ç©¶ã¯ãéåœã®ä»å·åžã«ãããŠãHIVéœæ§è ã®TORCHææã®è¡æž ç«åŠã調æ»ããããšãç®çãšããŠããŸããTORCHææã¯ããããœãã©ãºããæ¢ æ¯ã颚ç¹ãŠã€ã«ã¹ããµã€ãã¡ã¬ããŠã€ã«ã¹ïŒCMVïŒããã«ãã¹ãŠã€ã«ã¹ïŒHSVïŒãå«ã¿ãå ç«ãæå¶ãããåäœã«ãããŠé節ãªå䜵çãåŒãèµ·ããå¯èœæ§ããããŸãããã®ç ç©¶ã§ã¯ã2019幎ãã2021幎ã«ãããŠç¢ºèªãããHIVéœæ§è ããã®æ®åè¡æž ã䜿çšããŠãTORCHææã®è¡æž æç çã調æ»ããŸããã
ð¬ æ¹æ³
ç ç©¶ã«äœ¿çšãããã®ã¯ãä»å·åžå ¬è¡è¡çç°å¢ç ç©¶æã§ç¢ºèªããã100åã®HIVéœæ§è ããã®æ®åè¡æž ãµã³ãã«ã§ãããããã®ãµã³ãã«ã¯ããããœãã©ãºããæ¢ æ¯ã颚ç¹ãCMVãHSV-1ããã³HSV-2ã«å¯ŸããIgGããã³IgMæäœã枬å®ããããã«ãé µçŽ å ç«æž¬å®æ³ïŒELISAïŒãçšããŠåæãããŸããããŸããåæéã«æ¡åãããHIVé°æ§ã®è¡æž 100ãµã³ãã«ãæ¯èŒã®ããã«åæãããŸããã
ð äž»ãªãã€ã³ã
| ææç | HIVéœæ§è ã®IgGéœæ§ç | HIVé°æ§è ã®IgGéœæ§ç | ãªããºæ¯ (OR) | På€ |
|---|---|---|---|---|
| ãããœãã©ãºã | 11.1% | 3.0% | 3.97 | 0.046 |
| æ¢ æ¯ | 29.0% | 1.0% | 39.92 | <0.001 |
| CMV | 99.0% | 78.0% | 27.60 | <0.001 |
| HSV-1 | 96.0% | 87.0% | 3.56 | 0.039 |
| HSV-2 | 89.0% | 69.0% | 3.61 | <0.001 |
ð§ èå¯
ãã®ç ç©¶ã¯ãéåœã«ãããHIVéœæ§è ã®TORCHææã®è¡æž ç«åŠãåããŠå æ¬çã«èª¿æ»ãããã®ã§ããçµæãšããŠãHIVéœæ§è ã«ãããç¹å®ã®TORCHç åäœã®æç çãèããé«ãããšãæããã«ãªããŸãããç¹ã«ãæ¢ æ¯ãCMVã®ææçã¯éåžžã«é«ãããããã®ææçãHIVæ£è ã«ãããŠã©ã®ãããªåœ±é¿ãäžããããèæ ®ããå¿ èŠããããŸãããããã®çµæã¯ãå°åã®å ¬è¡è¡çæ¿çãæ£è ã±ã¢ã®è³æºé åã«ãããŠéèŠãªæéãšãªãã§ãããã
ð¡ å®ç掻ã¢ããã€ã¹
- 宿çãªHIVæ€æ»ãåããããšãéèŠã§ãã
- TORCHææã®ãªã¹ã¯ãçè§£ããå¿ èŠã«å¿ããŠæ€æ»ãåããããšãæ€èšããŸãããã
- å»çæ©é¢ãšé£æºããé©åãªäºé²çãè¬ããããšã倧åã§ãã
- å°åã®å ¬è¡è¡çæ å ±ãåžžã«ãã§ãã¯ããææçã®æµè¡ã«åããŸãããã
â ïž éç/課é¡
æ¬ç ç©¶ã«ã¯ããã€ãã®éçããããŸãããŸãããµã³ãã«ãµã€ãºã100åãšæ¯èŒçå°ãããããçµæã®äžè¬åã«ã¯æ³šæãå¿ èŠã§ãããŸããå°åç¹æã®èŠå ãä»ã®å°åã«é©çšã§ãããã©ããã¯äžæã§ããããã«ãæäœã®æç¡ãææã®éå»ã®å±¥æŽã瀺ããã®ã§ãããããçŸåšã®ææç¶æ³ãåæ ããŠããããã§ã¯ãããŸããã
ãŸãšã
æ¬ç ç©¶ã¯ãHIVæ£è ã«ãããTORCHææã®é ããè² æ ãæããã«ããå°åç¹æã®å ¬è¡è¡çæŠç¥ã®éèŠæ§ã匷調ããŠããŸãã宿çãªç£èŠã·ã¹ãã ã®ç¢ºç«ããHIVææè ã®å¥åº·ç®¡çã«ãããŠäžå¯æ¬ ã§ããããšã瀺ãããŸããã
ð é¢é£ãªã³ã¯é
- JAIDSïŒHIV/AIDSã«é¢ããæ å ±ïŒ
- CDCïŒã¢ã¡ãªã«çŸç äºé²ç®¡çã»ã³ã¿ãŒïŒ
- WHOïŒäžçä¿å¥æ©é¢ïŒ
åèæç®
| åé¡ | Unveiling the Hidden Burden of TORCH Infections in HIV Patients: A Residual Serum Seroepidemiological Study in a Korean Metropolitan City. |
|---|---|
| æ²èŒèª(幎) | Infect Chemother (2025 Dec) |
| DOI | doi: 10.3947/ic.2025.0105 |
| PubMed URL | https://pubmed.ncbi.nlm.nih.gov/41486442/ |
| PMID | 41486442 |
æžèªæ å ±
| DOI | 10.3947/ic.2025.0105 |
|---|---|
| PMID | 41486442 |
| PubMed URL | https://pubmed.ncbi.nlm.nih.gov/41486442/ |
| çºè¡å¹Ž | 2025 |
| èè å | Shi Hye Jin, Kim-Jeon Myung-Deok, Kim Jung-Hee, Kim Kyung-Ae, Park Yoonseon, Lee Juyeong, Hong Shin Hee, Song Jaeyong, Kim Meyong Hee, Kwon Munju, Eom Joong Sik |
| èè æå± | Division of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. / Incheon Metropolitan City Research Institute of Public Health and Environment, Incheon, Korea. / Division of Infectious Diseases, Department of Internal Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, Korea. 386js@naver.com. |
| éèªå | Infection & chemotherapy |